Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Return on Capital Employed (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Return on Capital Employed for 3 consecutive years, with 0.9% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed fell 40.0% to 0.9% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.9%, a 40.0% decrease, with the full-year FY2024 number at 0.82%, down 37.0% from a year prior.
  • Return on Capital Employed was 0.9% for Q3 2025 at Mereo BioPharma, down from 0.8% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.26% in Q4 2023 to a low of 0.9% in Q3 2025.
  • A 3-year average of 0.64% and a median of 0.67% in 2024 define the central range for Return on Capital Employed.
  • Peak YoY movement for Return on Capital Employed: plummeted -43bps in 2024, then decreased -16bps in 2025.
  • Mereo BioPharma's Return on Capital Employed stood at 0.26% in 2023, then plummeted by -164bps to 0.69% in 2024, then crashed by -31bps to 0.9% in 2025.
  • Per Business Quant, the three most recent readings for MREO's Return on Capital Employed are 0.9% (Q3 2025), 0.8% (Q2 2025), and 0.75% (Q1 2025).